Albany, NY (PRWEB) November 20, 2013
Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019
GBI Research has released the pharmaceutical report - “Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”. The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.
To check out the complete table of contents, visit: http://www.marketresearchreports.biz/analysis-details/prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019.
A brief introduction to prostate cancer, including the disease’s pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage.
In-depth analysis of drugs available for the treatment of prostate cancer, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.
Comprehensive review of the pipeline for prostate cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type.
Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.
Discussion of the drivers and barriers for market growth.
Discussion of the licensing and co-development deals landscape in prostate cancer, Includes an analysis of licensing deals by stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and co-development deals by year and value and network maps of licensing and co-development deals.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/179322.
Reasons to Buy
Table of Content
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Strong Growth Expected in Prostate Cancer Market
2.2 Novel Therapies Offer New Hope for Prostate Cancer Treatment
2.3 Large Pipeline, but High Failure Rate
3.1 Pathophysiology and Etiology
3.3 Disease Progression
4 Marketed Products
4.1 Hormonal Therapies
4.1.1 Zoladex (Goserelin) – AstraZeneca
4.1.2 Lupron Depot (Leuprolide acetate) – Abbvie
4.1.4 Firmagon (degarelix) – Ferring
4.1.5 Casodex (Bicalutamide)
4.2 Chemotherapy agents
4.2.1 Taxotere (Docetaxel) – Sanofi
4.2.2 Jevtana (Cabazitaxel) – Sanofi
4.3 Therapeutic Vaccines
4.3.1 Provenge (sipuleucel-T) – Dendreon
4.4 Targeted therapies (Second Generation Anti-androgens)
4.4.1 Zytiga (Abiraterone acetate) – Janssen
4.4.2 Xtandi (Enzalutamide) – Astellas/Medivation
4.5 Bone Metastasis Treatments
4.5.1 Xofigo (Radium 223) – Bayer/Algeta
4.5.2 Xgeva (denosumab) – Amgen
4.5.3 Zometa (zoledronic acid) – Novartis
4.6 Heat Map for Marketed Products
To buy the copy of this report, visit: http://www.marketresearchreports.biz/analysis/179322
5 Prostate Cancer Developmental Pipeline
5.1 Overall Pipeline
5.2 Mechanisms of Action
5.3 Clinical Trials
5.3.1 Attrition Rate
5.4 Key Late-Stage Pipeline Molecules
5.4.1 Cometriq (Cabozantinib) – Exelixis
5.4.2 OGX-011 (custirsen sodium) – Teva
5.4.3 TAK-700 (orteronel) – Takeda
5.4.4 ProstAtak (AdvTk+ valcyclovir) – Advantagene
5.4.5 ProstVac – Bavarian Nordic
5.4.6 Tasquinimod – Active Biotech
5.4.7 Yervoy (Ipilimumab) – Bristol-Myers Squibb
5.4.8 ARN-509 – Aragon Pharmaceuticals, Johnson and Jonhson
Global Automotive Battery Market 2012-2016: http://www.marketresearchreports.biz/analysis-details/global-automotive-battery-market-2012-2016
Global Automotive Battery market to grow at a CAGR of 6.9 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing R&D investment by the manufacturers. The Global Automotive Battery market has also been witnessing the increase in fuel cell vehicles. However, the slow acceptance of electric vehicles could pose a challenge to the growth of this market.
Global Automotive Battery Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Automotive Battery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Johnson Controls Inc., Exide Technologies, GS Yuasa Corp., East Penn Manufacturing Company Inc., Camel Group Co. Ltd., Fengfan Co. Ltd., and Fiamm Group.
Other vendors mentioned in the report are Chaowei Power Holdings Ltd., Douglas EnerSys Home, Hitachi Ltd., Huawei Corp., Shandong Sacred Sun Power Sources Co. Ltd., The Furukawa Battery, Zhejiang Haijiu Battery Co, and Zhejiang Narada Power Source Co. Ltd.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/179202.
Key questions answered in this report:
Global Lithium-ion Battery market to grow at a CAGR of 17.9 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand for Li-ion batteries in grid energy storage. The Global Lithium-ion Battery market has also been witnessing the advancement in technology. However, the high cost of Li-ion batteries could pose a challenge to the growth of this market.
Global Lithium-ion Battery Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Lithium-ion Battery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Panasonic Crop., Samsung SDI Co. Ltd., LG Chem Ltd., and Sony Electronics Inc.
Other vendors mentioned in the report are Amperex Technology Ltd., Build Your Dreams (BYD) Battery Co. Ltd., Boston-Power Inc., China BAK Battery Inc., Electrovaya Inc., EVE Energy Co. Ltd., Hitachi Maxell Ltd., Shandong Heter Lampson Electronic Co. Ltd, Tianjin Lishen Battery Co. Ltd, Valence Technology Inc.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/179203
Key questions answered in this report:
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948